BioAtla Inc.

Also on record

Records under this name other than the patents BioAtla Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 40 patents it holds.

Back to BioAtla Inc.

Patent	Title	Status	Expires	Confidence
US 9,683,048	Antibody Molecules to PD-1 and Uses Thereof conveyed to Costim Pharmaceuticals Inc. - now held by Novartis AG In force Term ends Jan 23, 2035 · High confidence	In force	Term ends Jan 23, 2035	High confidence
US 9,815,898	Antibody Molecules to PD-1 and Uses Thereof conveyed to Costim Pharmaceuticals Inc. - now held by Novartis AG In force Term ends Jan 23, 2035 · High confidence	In force	Term ends Jan 23, 2035	High confidence
US 9,908,936	Antibody Molecules to LAG-3 and Uses Thereof conveyed to Costim Pharmaceuticals Inc. - now held by Immutep S.A.S. In force Term ends Mar 13, 2035 · High confidence	In force	Term ends Mar 13, 2035	High confidence
US 12,252,535	Antibody Molecules to LAG-3 and Uses Thereof conveyed to Costim Pharmaceuticals Inc. - now held by Immutep S.A.S. In force Term ends Mar 13, 2035 · High confidence	In force	Term ends Mar 13, 2035	High confidence
US 12,600,777	Combination Therapies Comprising Antibody Molecules to LAG-3 conveyed to Costim Pharmaceuticals Inc. - now held by Novartis AG In force Term ends Mar 13, 2035 · Low confidence	In force	Term ends Mar 13, 2035	Low confidence
US 10,711,060	Antibody Molecules to LAG-3 and Uses Thereof conveyed to Costim Pharmaceuticals Inc. - now held by Novartis AG In force Term ends Mar 26, 2035 · High confidence	In force	Term ends Mar 26, 2035	High confidence
US 10,752,687	Antibody Molecules to PD-1 and Uses Thereof conveyed to Costim Pharmaceuticals Inc. - now held by Novartis AG In force Term ends Aug 24, 2035 · High confidence	In force	Term ends Aug 24, 2035	High confidence
US 9,988,452	Antibody Molecules to PD-L1 and Uses Thereof conveyed to Costim Pharmaceuticals Inc. - now held by Novartis AG In force Term ends Oct 13, 2035 · High confidence	In force	Term ends Oct 13, 2035	High confidence
US 11,827,704	Antibody Molecules to PD-1 and Uses Thereof conveyed to Costim Pharmaceuticals Inc. - now held by Novartis AG In force Term ends Jun 8, 2036 · High confidence	In force	Term ends Jun 8, 2036	High confidence
US 12,187,801	Chimeric Antigen Receptors Against Axl or ROR2 and Methods of Use Thereof now held by Inc., BioAtla In force Term ends Jun 30, 2036 · Medium confidence	In force	Term ends Jun 30, 2036	Medium confidence

10 of 53 records shown.

Pro members see all 53.

Pro members: see all 53 records